Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Arrowhead Pharmaceuticals Inc

ARWR ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Large Cap Analyst: BUY

Last Close

$86.64

▲ +1.23%

Market Cap $12.24B · Vol 335.06K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$12.24B

Large Cap

Div Yield

N/A

EPS Growth

-35,511.00%

YoY

RSI (14)

52.61

Momentum

Beta

1.28

vs Market

52W High

$95.43

9.21% below

52W Low

$18.74

362.33% above

Volume

335.06K

Avg 689.28K

P/B

10.04

Price-to-book

ROE

-0.50%

Return on equity

Free Float

96.25%

Public shares

Shariah Compliance8 STANDARDS

✗ Arrowhead Pharmaceuticals Inc (ARWR) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ARWR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.15%

+20.48%

+8.72%

+35.76%

YTD

+30.50%

+361.34%

+195.20%

+43.16%

Financials & Valuation

TTM · Annual

Total Revenue	$829.45M
Net Income	$30.11M
Revenue Growth (YoY)	+171.02%
Gross Margin	100.00%
Operating Margin	11.86%
Net Profit Margin	3.63%
ROE	-0.50%
ROA · ROIC	4.08% · 4.93%

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	5.56
P/B	10.04
P/FCF	29.41
EPS Growth	-35,511.00%
Outstanding Shares	141.25M

Technical Indicators

50-Day SMA	$81.02
200-Day SMA	$67.66
RSI (14)	52.61
Beta	1.28
52-Week High	$95.43
52-Week Low	$18.74

Volume Today	335.06K
Avg Daily Volume (30D)	689.28K
Relative Volume	0.49x
Volatility (10D)	33.81
Volatility (30D)	66.87
Free Float	96.25%

Analyst Consensus

BUY

Current Price $86.64

Mean Target $110.06

52W Low$18.74 52W High$95.43

Current

Target

$18.74 $95.43

Current Analyst target

+27.03% upside potential · 14 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SGT8G5

ISINUS04280A1007

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 23, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.